Teva Pharmaceutical Industries Limited
TEVA | NYSE
$39.87
-$0.19 (-0.47%)
Sep 22, 2026, 11:25 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 17.26B | 16.54B | 15.85B | 14.93B | 15.88B | 16.66B |
Cost of Revenue | 8.32B | 8.48B | 8.2B | 7.95B | 8.28B | 8.93B |
Gross Profit | 8.94B | 8.06B | 7.65B | 6.97B | 7.59B | 7.73B |
Operating Income | 2.16B | -303M | 433M | -2.2B | 1.72B | -3.57B |
Interest Income | n/a | n/a | 68M | n/a | n/a | 24M |
Pretax Income | 1.24B | -1.28B | -622M | -3.14B | 667M | -3.93B |
Net Income | 1.41B | -1.64B | -559M | -2.45B | 417M | -3.99B |
Selling & General & Admin | 3.97B | 3.7B | 3.5B | 3.45B | 3.53B | 3.67B |
Research & Development | 1.01B | 1.06B | 953M | 838M | 1.09B | 1.79B |
Other Expenses | 1.79B | 3.61B | 2.76B | 4.89B | 1.26B | 5.83B |
Operating Expenses | 6.78B | 8.37B | 7.21B | 9.17B | 5.88B | 11.3B |
Interest Expense | 916M | 941M | 1.03B | 930M | 891M | 755M |
Selling & Marketing Expenses | 2.69B | 2.54B | 2.34B | 2.27B | 2.43B | 2.5B |
Cost & Expenses | 15.1B | 16.85B | 15.41B | 17.12B | 14.16B | 20.23B |
Income Tax Expense | -180M | 676M | -7M | -643M | 211M | 168M |
Shares Outstanding (Basic) | 1.15B | 1.13B | 1.12B | 1.11B | 1.1B | 1.1B |
Shares Outstanding (Diluted) | 1.17B | 1.13B | 1.12B | 1.11B | 1.11B | 1.1B |
EPS (Basic) | 1.23 | -1.45 | -0.50 | -2.20 | 0.38 | -3.64 |
EPS (Diluted) | 1.20 | -1.45 | -0.50 | -2.20 | 0.38 | -3.64 |
EBITDA | 3.14B | 4.43B | 1.56B | -925M | 4.41B | 4.61B |
EBIT | 2.14B | 3.37B | 405M | -2.23B | 3.08B | 3.06B |
Depreciation & Amortization | 1B | 1.06B | 1.15B | 1.31B | 1.33B | 1.56B |
Add to Watchlist
Select watchlists to add or remove TEVA